To our knowledge, this is the first study that has validated TRB3 as a therapeutic target in animal models of retinal degeneration; this study emphasizes the critical need to generate a TRB3-based cellular therapy to retard inherited retinal dystrophies. Here, TRIB3 is linked to retinal degeneration.